

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF  
SECURITIES**

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Bayer World Investments B.V.</u> _____ (Last) (First) (Middle) ENERGIEWEG 1 _____ (Street) MIJDRECHT P7 3641RT _____ (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 10/07/2021	3. Issuer Name and Ticker or Trading Symbol <u>Pyxis Oncology, Inc. [ PYXO ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
---------------------------------	---	--	---

**Table II - Derivative Securities Beneficially Owned  
(e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A Convertible Preferred Stock	(1)	(1)	Common Stock	1,786,831 <sup>(2)</sup>	(2)	D <sup>(3)</sup>	
Series B Convertible Preferred Stock	(1)	(1)	Common Stock	955,507 <sup>(2)</sup>	(2)	D <sup>(3)</sup>	

1. Name and Address of Reporting Person* <u>Bayer World Investments B.V.</u> _____ (Last) (First) (Middle) ENERGIEWEG 1 _____ (Street) MIJDRECHT P7 3641RT _____ (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person* <u>BAYER AKTIENGESELLSCHAFT</u> _____ (Last) (First) (Middle) BAYERWERK, GEBAEUDE W11 KAISER-WILHELM-ALLEE 1 _____ (Street) LEVERKUSEN 2M 51373 _____ (City) (State) (Zip)		
---	--	--

**Explanation of Responses:**

1. Shares of Series A and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") have no expiration date and, as of the date of this filing, are convertible, at the

